Hypofractionated radiation therapy for localized prostate cancer (first experience)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This paper presents a study of 74 prostate cancer patients divided into 2 groups (study group and comparison group). The comparison group patients (n=50) were treated with radiation therapy in standard fractionated mode, while study group patients (n=24) underwent hypofractionated radiation therapy (STD 7.5 Gy; TTD 37.5 Gy). Early radiation-induced complications occurred only in the comparison group patients. Late radiation-induced complications were observed in 4 and 8 patients in the study group and the comparison group, respectively. Significant statistic differences in quality of life between groups were found in patients with excellent (FET; p=0.0145) and satisfactory (FET; p=0.03) well-being. Hypofractionated radiation therapy is safe given that the necessary technical and clinical conditions are observed. It significantly reduces treatment time and enables quickly bringing a course of radiation therapy to radical doses. This is a noninvasive treatment that significantly reduces risks and cost of procedures.

Full Text

Restricted Access

About the authors

T. G Vorob'eva

Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy

I. V Bednyj

Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy

Email: p_filatov@nricp .ru

E. A Drobjazgin

Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy; Novosibirsk State Medical University

Email: evgenyidrob@inbox.ru

E. S Polovnikov

Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy

Email: drojo@mail.ru

References

  1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и в странах СНГ в 2012 году. М.: Издательская группа РОНЦ. 2014. 226 с
  2. Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiation Oncology. 2011; 6:3.
  3. Katz A.J., Santoro M., Ashley R., Katz A.J., Santoro M., Ashley R. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Cancer Res. Treat. 2010;9(6):575-582.
  4. Lukka H., Hayter C., Julian J.A., Lukka H., Hayter C., Julian J.A. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol. 2005;23(25):6132-6138.
  5. McBride S.M., Wong D.S., Dombrowski J.J., Harkins B., Tapella P., Hanscom H.N., Collins S.P., Kaplan I.D. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118(15):3681-3690.
  6. Alongi F., Cozzi L., Arcangeli S., Iftode C., Comito T., Villa E., Lobefalo F., Navarria P., Reggiori G., Mancosu P., Clerici E., Fogliata A., Tomatis S., Taverna G., Graziotti P., Scorsetti M. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology. 2013; 8: 171.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies